Presented at AACR 2024: Researchers sought to determine how knocking out Fc gamma receptors in a super immunodeficient mouse model would alter efficacy of an IgG4 mAb checkpoint inhibitor (anti-PD1). Overall, they remark that FcResolv® NOG strains represent a cleaner system for efficacy studies of antibody-based therapies which remove potential confounding variables due to interactions with murine Fc gamma receptors.
View the study below to learn more and connect with an expert.